Published in J Biol Chem on January 27, 2003
Targeted deletion of hepatocyte ABCA1 leads to very low density lipoprotein triglyceride overproduction and low density lipoprotein hypercatabolism. J Biol Chem (2010) 1.11
ATP-binding membrane cassette transporter A1 (ABCA1): a possible link between inflammation and reverse cholesterol transport. Mol Med (2010) 1.10
Intestinal lipid absorption and lipoprotein formation. Curr Opin Lipidol (2014) 0.97
Association of ABCA1 with syntaxin 13 and flotillin-1 and enhanced phagocytosis in tangier cells. Mol Biol Cell (2004) 0.93
Decreased lipid efflux and increased susceptibility to cholesterol-induced apoptosis in macrophages lacking phosphatidylcholine transfer protein. Biochem J (2005) 0.86
Origins of intestinal ABCA1-mediated HDL-cholesterol. J Lipid Res (2008) 0.83
Characterization of apoA-I-dependent lipid efflux from adipocytes and role of ABCA1. Mol Cell Biochem (2010) 0.82
Brefeldin A inhibits cholesterol efflux without affecting the rate of cellular uptake and re-secretion of apolipoprotein A-I in adipocytes. Arch Biochem Biophys (2008) 0.82
BIG1, a brefeldin A-inhibited guanine nucleotide-exchange protein modulates ATP-binding cassette transporter A-1 trafficking and function. Arterioscler Thromb Vasc Biol (2012) 0.80
Lipid rafts: dream or reality for cholesterol transporters? Eur Biophys J (2007) 0.79
Hepatocyte ABCA1 Deletion Impairs Liver Insulin Signaling and Lipogenesis. Cell Rep (2017) 0.75
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med (2008) 43.36
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science (2004) 21.65
New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet (2010) 17.89
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (2012) 12.10
Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med (2006) 11.72
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet (2009) 10.52
Meta-analysis and imputation refines the association of 15q25 with smoking quantity. Nat Genet (2010) 8.55
LDL-cholesterol concentrations: a genome-wide association study. Lancet (2008) 6.44
A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. Nat Genet (2009) 6.31
2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol (2013) 5.97
2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol (2009) 5.65
Medical sequencing at the extremes of human body mass. Am J Hum Genet (2007) 5.61
The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol (2010) 5.54
Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med (2014) 5.47
Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med (2014) 4.94
A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med (2009) 4.46
Genetic variants influencing circulating lipid levels and risk of coronary artery disease. Arterioscler Thromb Vasc Biol (2010) 4.08
Common variants at 10 genomic loci influence hemoglobin A₁(C) levels via glycemic and nonglycemic pathways. Diabetes (2010) 4.07
HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet (2010) 4.07
Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol (2006) 4.02
Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation (2009) 3.98
Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease. N Engl J Med (2016) 3.88
Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. CMAJ (2003) 3.85
Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21
Design of the Coronary ARtery DIsease Genome-Wide Replication And Meta-Analysis (CARDIoGRAM) Study: A Genome-wide association meta-analysis involving more than 22 000 cases and 60 000 controls. Circ Cardiovasc Genet (2010) 3.15
Gene dosage of the common variant 9p21 predicts severity of coronary artery disease. J Am Coll Cardiol (2010) 3.07
Inherited thrombophilia and preeclampsia within a multicenter cohort: the Montreal Preeclampsia Study. Am J Obstet Gynecol (2008) 2.82
Functional analysis of the chromosome 9p21.3 coronary artery disease risk locus. Arterioscler Thromb Vasc Biol (2009) 2.79
Rare copy number variation discovery and cross-disorder comparisons identify risk genes for ADHD. Sci Transl Med (2011) 2.29
Genetically determined height and coronary artery disease. N Engl J Med (2015) 2.24
The cardiovascular effects of peroxisome proliferator-activated receptor agonists. Am J Med (2012) 2.15
A genome-wide association study reveals variants in ARL15 that influence adiponectin levels. PLoS Genet (2009) 2.09
Genome-wide linkage and association analyses to identify genes influencing adiponectin levels: the GEMS Study. Obesity (Silver Spring) (2009) 2.07
Elevated homocysteine reduces apolipoprotein A-I expression in hyperhomocysteinemic mice and in males with coronary artery disease. Circ Res (2006) 1.99
The nested case-control study in cardiology. Am Heart J (2003) 1.84
Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial. Clin Chem (2011) 1.79
Disruption at the PTCHD1 Locus on Xp22.11 in Autism spectrum disorder and intellectual disability. Sci Transl Med (2010) 1.75
Stress pathways to spontaneous preterm birth: the role of stressors, psychological distress, and stress hormones. Am J Epidemiol (2009) 1.72
A genome-wide association search for type 2 diabetes genes in African Americans. PLoS One (2012) 1.72
A new method for measurement of total plasma PCSK9: clinical applications. J Lipid Res (2010) 1.64
Kinesin family member 6 variant Trp719Arg does not associate with angiographically defined coronary artery disease in the Ottawa Heart Genomics Study. J Am Coll Cardiol (2009) 1.64
Lack of MEF2A mutations in coronary artery disease. J Clin Invest (2005) 1.62
Abdominal aortic aneurysm is associated with a variant in low-density lipoprotein receptor-related protein 1. Am J Hum Genet (2011) 1.60
A novel efflux-recapture process underlies the mechanism of high-density lipoprotein cholesteryl ester-selective uptake mediated by the low-density lipoprotein receptor-related protein. Arterioscler Thromb Vasc Biol (2004) 1.59
Lack of support for the association between GAD2 polymorphisms and severe human obesity. PLoS Biol (2005) 1.59
Clinical and public health assessment of benefits and risks of statins in primary prevention of coronary events: resolved and unresolved issues. Can J Cardiol (2008) 1.59
Homocysteine-betaine interactions in a murine model of 5,10-methylenetetrahydrofolate reductase deficiency. FASEB J (2003) 1.59
Exome sequencing in suspected monogenic dyslipidemias. Circ Cardiovasc Genet (2015) 1.51
Shared genetic susceptibility to ischemic stroke and coronary artery disease: a genome-wide analysis of common variants. Stroke (2013) 1.51
The LDLR deficient mouse as a model for aortic calcification and quantification by micro-computed tomography. Atherosclerosis (2011) 1.50
Discordance between Framingham Risk Score and atherosclerotic plaque burden. Eur Heart J (2013) 1.46
Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). Circ Cardiovasc Qual Outcomes (2009) 1.46
Molecular and cellular physiology of apolipoprotein A-I lipidation by the ATP-binding cassette transporter A1 (ABCA1). J Biol Chem (2003) 1.44
Regional distribution and metabolic effect of PCSK9 insLEU and R46L gene mutations and apoE genotype. Can J Cardiol (2013) 1.39
Genetic and phenotypic architecture of metabolic syndrome-associated components in dyslipidemic and normolipidemic subjects: the GEMS Study. Atherosclerosis (2007) 1.36
A genome-wide association study for coronary artery disease identifies a novel susceptibility locus in the major histocompatibility complex. Circ Cardiovasc Genet (2012) 1.35
Relation between atherogenic dyslipidemia and the Adult Treatment Program-III definition of metabolic syndrome (Genetic Epidemiology of Metabolic Syndrome Project). Am J Cardiol (2005) 1.32
Triglycerides and heart disease: still a hypothesis? Arterioscler Thromb Vasc Biol (2011) 1.32
Association of functionally significant Melanocortin-4 but not Melanocortin-3 receptor mutations with severe adult obesity in a large North American case-control study. Hum Mol Genet (2008) 1.30
Cardiometabolic risk in Canada: a detailed analysis and position paper by the cardiometabolic risk working group. Can J Cardiol (2011) 1.24
Improved prediction of cardiovascular disease based on a panel of single nucleotide polymorphisms identified through genome-wide association studies. Circ Cardiovasc Genet (2010) 1.23
The HDL proteome in acute coronary syndromes shifts to an inflammatory profile. Biochim Biophys Acta (2011) 1.23
Chronic inflammatory diseases and cardiovascular risk: a systematic review. Can J Cardiol (2011) 1.21
Residual macrovascular risk in 2013: what have we learned? Cardiovasc Diabetol (2014) 1.20
Galactose enhances oxidative metabolism and reveals mitochondrial dysfunction in human primary muscle cells. PLoS One (2011) 1.19
Biogenesis and speciation of nascent apoA-I-containing particles in various cell lines. J Lipid Res (2005) 1.18
A systems biology framework identifies molecular underpinnings of coronary heart disease. Arterioscler Thromb Vasc Biol (2013) 1.18
RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo. J Am Coll Cardiol (2010) 1.17
Isolated aerobic exercise and weight loss: a systematic review and meta-analysis of randomized controlled trials. Am J Med (2011) 1.16
Identification of an ABCA1-dependent phospholipid-rich plasma membrane apolipoprotein A-I binding site for nascent HDL formation: implications for current models of HDL biogenesis. J Lipid Res (2007) 1.16
Molecular interactions between apoE and ABCA1: impact on apoE lipidation. J Lipid Res (2004) 1.15
Mid-trimester maternal plasma cytokines and CRP as predictors of spontaneous preterm birth. Cytokine (2009) 1.15
Cellular physiology of cholesterol efflux in vascular endothelial cells. Circulation (2004) 1.15
Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference. Can J Cardiol (2011) 1.12
Harmonization of guidelines for the prevention and treatment of cardiovascular disease: the C-CHANGE Initiative. CMAJ (2011) 1.12
Molecular regulation of SREBP function: the Insig-SCAP connection and isoform-specific modulation of lipid synthesis. Biochem Cell Biol (2004) 1.12
Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review. Am J Med (2009) 1.11
Clinical and genetic association of serum paraoxonase and arylesterase activities with cardiovascular risk. Arterioscler Thromb Vasc Biol (2012) 1.10
Decreased mitochondrial proton leak and reduced expression of uncoupling protein 3 in skeletal muscle of obese diet-resistant women. Diabetes (2002) 1.10
Clinical and genetic association of serum ceruloplasmin with cardiovascular risk. Arterioscler Thromb Vasc Biol (2011) 1.10
Rosuvastatin for primary prevention among individuals with elevated high-sensitivity c-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for "intermediate risk". Circ Cardiovasc Qual Outcomes (2010) 1.09
A cluster randomized controlled Trial to Evaluate an Ambulatory primary care Management program for patients with dyslipidemia: the TEAM study. CMAJ (2010) 1.09
Comparative genome-wide association studies in mice and humans for trimethylamine N-oxide, a proatherogenic metabolite of choline and L-carnitine. Arterioscler Thromb Vasc Biol (2014) 1.08
Adipocyte low density lipoprotein receptor-related protein gene expression and function is regulated by peroxisome proliferator-activated receptor gamma. J Biol Chem (2003) 1.08
Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. Am J Cardiol (2003) 1.07
WW-domain-containing oxidoreductase is associated with low plasma HDL-C levels. Am J Hum Genet (2008) 1.06
Genetic etiology of isolated low HDL syndrome: incidence and heterogeneity of efflux defects. Arterioscler Thromb Vasc Biol (2007) 1.06
Protein-Truncating Variants at the Cholesteryl Ester Transfer Protein Gene and Risk for Coronary Heart Disease. Circ Res (2017) 1.06
Gene expression profiling in whole blood identifies distinct biological pathways associated with obesity. BMC Med Genomics (2010) 1.05
Effect of obesity on high-density lipoprotein metabolism. Obesity (Silver Spring) (2007) 1.05
cAMP induces ABCA1 phosphorylation activity and promotes cholesterol efflux from fibroblasts. J Lipid Res (2002) 1.05
Prevalence of dyslipidemia in statin-treated patients in Canada: results of the DYSlipidemia International Study (DYSIS). Can J Cardiol (2010) 1.05
Compound heterozygosity at the sphingomyelin phosphodiesterase-1 (SMPD1) gene is associated with low HDL cholesterol. Hum Genet (2003) 1.04